Cargando…
Long-Term 5-Year Response to Pembrolizumab, Bevacizumab, and Capecitabine Regimen in a Metastatic Colon Cancer Patient with MSI-High and KRAS Mutation: Case Report
With an estimated 1.88 million new cases and 0.92 million deaths in 2020, colorectal cancer accounts for nearly one-tenth of all new cancer and cancer-related deaths worldwide. Nearly half of the patients of colorectal cancer are diagnosed with metastatic or inoperable disease with a very dismal 5-y...
Autores principales: | Julka, Pramod Kumar, Arya, Deepika, Gupta, Kush |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601776/ https://www.ncbi.nlm.nih.gov/pubmed/37900837 http://dx.doi.org/10.1159/000533760 |
Ejemplares similares
-
Personalized Treatment Approach to Metastatic Castration-Resistant Prostate Cancer with BRCA2 and PTEN Mutations: A Case Report
por: Julka, Pramod Kumar, et al.
Publicado: (2020) -
The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011) -
Influence of MSI and 18q LOH markers on capecitabine adjuvant monotherapy in colon cancer patients
por: Matevska-Geshkovska, Nadica, et al.
Publicado: (2018) -
Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013) -
Coexistence of MSI with KRAS mutation is associated with worse prognosis in colorectal cancer
por: Hu, Jing, et al.
Publicado: (2016)